High expression of MAGE-A9 is associated with unfavorable survival in esophageal squamous cell carcinoma
Authors:
Open Access
- 20 July 2017
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (3) , 3415-3420
Abstract
Melanoma-associated antigens (MAGEs) are a group of well-characterized members of the cancer/testis antigen family, which are expressed in a variety of malignant tumors. MAGE-A9, a subfamily of MAGE-As, has been studied in a number of types of cancer and have been associated with unfavorable survival outcome. However, the expression of MAGE-A9 in human esophageal squamous cell carcinoma (ESCC) and association of MAGE-A9 with the clinicopathological characteristics of ESCC, particularly prognostic characteristics, remains unknown. The present study aimed at determining the expression level of MAGE-A9 and at evaluating its clinical significance in human ESCC. Quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC) analyses were performed to characterize the expression of MAGE-A9 in ESCC tissues. Kaplan-Meier estimator survival and Cox's regression analyses were used to evaluate the prognosis of 103 patients with ESCC. The results of qPCR and IHC analysis revealed that the expression of MAGE-A9 was significantly increased in ESCC tissues, compared with that in healthy tissues. Furthermore, the expression level of MAGE-A9 protein in ESCC was significantly associated with the pathological grade (P=0.008), tumor size (P=0.027) and lymph node metastasis (P=0.009). Multivariate analysis using Cox's regression model identified that the expression level of MAGE-A9 and lymph node metastasis were independent prognostic factors for the overall survival rate of patients with ESCC (P=0.006 and P=0.001, respectively). The results of the present study are, to the best of our knowledge, the first to indicate that MAGE-A9 expression is a valuable prognostic biomarker for ESCC and that it may serve as a targeted therapy in the treatment of ESCC. Increased expression of MAGE-A9 indicated an unfavorable survival outcome in patients with ESCC.Keywords
This publication has 23 references indexed in Scilit:
- Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical studyJournal of Cancer Research and Clinical Oncology, 2011
- Melanoma-associated antigen genes – An updateCancer Letters, 2011
- Cancer–testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rateEuropean Journal of Cancer, 2011
- Mage-A Cancer/Testis Antigens Inhibit p53 Function by Blocking Its Interaction with ChromatinCancer Research, 2010
- Clinical Significance of Melanoma Antigen-Encoding Gene-1 (MAGE-1) Expression and its Correlation with Poor Prognosis in Differentiated Advanced Gastric CancerAnnals of Surgical Oncology, 2010
- Prognostic Significance of MAGE in Peritoneal Washes in Gastric Carcinoma Patients Without Peritoneal MetastasisJournal of Clinical Gastroenterology, 2010
- Prognostic value of MAGE‐A and NY‐ESO‐1 expression in pharyngeal cancerHead & Neck, 2010
- High frequency of MAGE‐A4 and MAGE‐A9 expression in high‐risk bladder cancerInternational Journal of Cancer, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Expression of MAGE-antigens in normal tissues and cancerInternational Journal of Cancer, 2000